patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

amoxicillin + clarithromycin + vonoprazan

Marketedupdated 2mo ago

by $PHAT Phathom Pharmaceuticals, Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 49 investigational indications.

all catalysts(6)

approval · 6

News(0)

no news has mentioned this drug yet

brand

Voquezna Triple Pak

generic

amoxicillin + clarithromycin + vonoprazan [INN]

MOA

12.1 Mechanism of Action Vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell through inhibition of the H + , K + -ATPase enzyme system in a potassium competitive manner. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step of acid production. Vonoprazan does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states. Vonoprazan binds to the active proton pumps in a noncovalent and reversible manner. Amoxicillin is an antibacterial drug. Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4) ]. Acid suppression enhances the replication of H. pylori bacteria and the stability and effectiveness of antimicrobials in the treatment of H. pylori infection.

indication

Helicobacter pylori Infections

phase

marketed

amoxicillin + clarithromycin + vonoprazan

all catalysts(6)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (2)

FDA exclusivities (2)

🐶 often sniffed alongside